Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly price for cash-paying U.S. patients with Type 2 diabetes from its previous list price of nearly $1,

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to use GoodRx to self-pay for both Ozempic and Wegovy at the $499-per-month price at 70,000 U.S. retail pharmacies.

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar Mike Doustdar, the company isn't making a point to rapidly add staffers.

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access manufacturer-sponsored savings at t

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 pharmacies.

The legal battle over Ozempic is getting bigger by the day. Multiple lawsuits have been filed against the diabetes-medicine-turned weight-loss drug. What started as scattered complaints has grown into more than a thousand lawsuits against Novo Nordisk.